Weekly Cumulative RSV Vaccination Coverage and Intent, Overall, by Selected Demographics and Jurisdiction, Among Adults 75 and Older and 60-74 Years with High-Risk Conditions Ever Vaccinated, United States

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction • Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html). • In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.

• 基于人口统计学特征与行政辖区划分的、75岁及以上成人，以及合并高危疾病且曾接种呼吸道合胞病毒（Respiratory Syncytial Virus, RSV）疫苗的60-74岁成人的周度累计RSV疫苗接种覆盖率与接种意愿
• 针对75岁及以上老年人群与合并高危疾病的60-74岁成人，其RSV疫苗接种覆盖率与接种意愿的周度估算值，均通过美国国家免疫接种调查成人新冠模块（National Immunization Survey–Adult COVID Module, NIS-ACM）的数据计算得出，数据来源：https://www.cdc.gov/nis/about/index.html
• 2023年6月，美国免疫实践咨询委员会（Advisory Committee on Immunization Practices, ACIP）投票通过推荐方案：60岁及以上成人可通过共享临床决策模式接种单剂次RSV疫苗。2024年6月，ACIP再次更新推荐，为所有75岁及以上成人，以及罹患重症RSV疾病风险升高的60-74岁成人接种单剂次RSV疫苗。本次数据集收录了60岁及以上成人曾接种至少一剂RSV疫苗的相关数据。